A Phase 3 clinical trial evaluating linaclotide has reached completed status as of May 14, 2026. The study, registered as NCT05652205, was titled "A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation."
The trial compared linaclotide against placebo in pediatric subjects between the ages of 2 and 5 who had functional constipation. According to the registry record, the study's status has now been updated to completed.
No results, efficacy outcomes, or safety findings from this trial have been provided in this update. The completion status reflects only that the trial has concluded, not any specific conclusions about adverse events or symptom changes. Readers should not infer benefit or harm from this status update alone.
Linaclotide is an approved compound, and this pediatric study represents one part of its ongoing clinical research record. Further details about study results, if and when posted, would appear in future updates to the trial registry.
For more background on linaclotide, readers can consult the compound overview.